Improving outcomes for patients through new and innovative antibiotics.
AstraZeneca is committed to discovering and developing compounds to improve patient care in antibiotics
AstraZeneca is one of few large pharmaceutical companies with a strong late-stage pipeline for antibiotics. We are focusing on the fast growing global health threat of multidrug resistant bacterial infections and continue to bring scientific innovation from our antibiotics portfolio to doctors and patients around the world. We are committed to collaborating with stakeholders and partnering with governments as we aim to ensure the availability of effective new treatments for patients with life-threatening infections.
The challenges we face
Antibiotics have been heralded as one of the greatest breakthroughs of modern medicine. But in recent years we have seen the rapid development of resistant bacteria. As a result we could be entering into a post-antibiotic era, where antibiotics no longer work and minor infections could kill. Read on to learn about some of the most problematic bacteria and explore the impact of antibiotic resistance on modern medicine.
The usual suspects
Antibiotics stand between us and a world where common infections and minor injuries could kill. We take a closer look at six problematic bacteria, against which certain antibiotics are becoming less effective.
Back to the future
Since their introduction in the 1940s, antibiotics have helped drive the transformation of modern medicine. However, with the rise of antibiotic resistance, we run the risk of losing many of the advances that we take for granted. In this article, we explore some of the key concerns surrounding healthcare in the post-antibiotic era.
An exciting pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Infection, Neuroscience and Gastrointestinal (as at 29 April 2016)
AstraZeneca is one of few large pharmaceutical companies with a strong late-stage pipeline for antibiotics and we are working towards a reinvigorated global environment for antibiotic research, development and commercialisation. Antimicrobial resistance is a growing global health threat which could undermine the achievements of modern medicine. We are committed to collaborating with stakeholders and partnering with governments as we aim to tackle this challenge and ensure the availability of effective new treatments for patients with life-threatening infections.